Last updated: 2026-10-13 13:36:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Alaunos Therapeutics, Inc. (TCRT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.97, with a market capitalization of $2.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.72 to $4.50. This page covers its latest market performance, valuation, price trends and company information.
$2.00M | |
$1.02 | |
$601.50 | |
$0.72 | |
$1.05 | |
75.28M | |
865.10K | |
-- | |
$4.50 | |
$0.72 | |
-- | |
-- |
Alaunos Therapeutics, Inc. (TCRT) is currently trading at $1.97 as of 2026-10-13 13:35:00, up 87.24% ($0.92) from the previous close of $1.05
During today's regular trading session, TCRT has traded between $0.72 and $601.50, with a trading volume of 75.28M shares. The current price is near the lower end of today's range.
Over the past seven days, Alaunos Therapeutics, Inc. (TCRT) moved from $0.82 to $1.97, representing a gain of 139.76% ($1.15).
The stock traded between $0.72 and $2.49 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 590.82 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 33.0%
TCRT is currently trading at $1.97, placing it 33.0% of the way from its 52-week low of $0.72 to its 52-week high of $4.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alaunos Therapeutics, Inc. (TCRT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.